|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 March 2001, Vol. 97, No. 5, pp. 1388-1391
NEOPLASIA
CD4+ cutaneous T-cell lymphoma cells express the
p140-killer cell immunoglobulin-like receptor
Martine Bagot,
Alessandro Moretta,
Simona Sivori,
Roberto Biassoni,
Claudia Cantoni,
Cristina Bottino,
Laurence Boumsell, and
Armand Bensussan
From INSERM U448 and Service de Dermatologie de
l'hopital Henri Mondor, (AP-HP) Creteil, France; Dipartimento di
Medicina Sperimentale, Università di Genova, and Istituto
Nazionale per la Ricerca sul Cancro, Genova, Italy.
Tumor cells of patients with cutaneous T-cell lymphoma (CTCL)
have the cell surface phenotype of mature T-helper lymphocytes, and it
may be impossible to differentiate them from nonmalignant lymphocytes
in skin and blood. Until now, no specific cell membrane marker of CTCL
has been reported. In the current study, it is reported for the first
time that CTCL cells express the major histocompatibility complex class
I binding p140-killer cell immunoglobulin-like receptor, which has
been described on a minor subset of natural killer lymphocytes and on a
marginal circulating CD8+ T lymphocyte subset.
Interestingly, the molecular characterization of this KIR expressed by
CTCL allowed us to isolate a novel allelic form of p140-KIR3DL,
resulting in 4 amino acid substitutions, 3 in the extracellular
immunoglobulin-like domain of the protein and one in the cytoplasmic
region. This finding is likely to be important both for the
pathophysiology and for the clinical treatment of patients with CTCL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Fourmentraux-Neves, A. Jalil, S. Da Rocha, C. Pichon, S. Chouaib, G. Bismuth, and A. Caignard
Two opposite signaling outputs are driven by the KIR2DL1 receptor in human CD4+ T cells
Blood,
September 15, 2008;
112(6):
2381 - 2389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Marie-Cardine, D. Huet, N. Ortonne, N. Remtoula, S. L. Gouvello, M. Bagot, and A. Bensussan
Killer cell Ig-like receptors CD158a and CD158b display a coactivatory function, involving the c-Jun NH2-terminal protein kinase signaling pathway, when expressed on malignant CD4+ T cells from a patient with Sezary syndrome
Blood,
June 1, 2007;
109(11):
5064 - 5065.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Ortonne, D. Huet, C. Gaudez, A. Marie-Cardine, V. Schiavon, M. Bagot, P. Musette, and A. Bensussan
Significance of circulating T-cell clones in Sezary syndrome
Blood,
May 15, 2006;
107(10):
4030 - 4038.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Munitz, I. Bachelet, R. Eliashar, A. Moretta, L. Moretta, and F. Levi-Schaffer
The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils
Blood,
March 1, 2006;
107(5):
1996 - 2003.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Huet, M. Bagot, D. Loyaux, J. Capdevielle, L. Conraux, P. Ferrara, A. Bensussan, and A. Marie-Cardine
SC5 mAb Represents a Unique Tool for the Detection of Extracellular Vimentin as a Specific Marker of Sezary Cells
J. Immunol.,
January 1, 2006;
176(1):
652 - 659.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Williams, A. R. Bateman, and S. I. Khakoo
HANGING IN THE BALANCE: KIR and Their Role in Disease
Mol. Interv.,
August 1, 2005;
5(4):
226 - 240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. van Doorn, R. Dijkman, M. H. Vermeer, J. J. Out-Luiting, E. M. H. van der Raaij-Helmer, R. Willemze, and C. P. Tensen
Aberrant Expression of the Tyrosine Kinase Receptor EphA4 and the Transcription Factor Twist in Sezary Syndrome Identified by Gene Expression Analysis
Cancer Res.,
August 15, 2004;
64(16):
5578 - 5586.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Musette, L. Michel, F. Jean-Louis, M. Bagot, and A. Bensussan
Polymorphic expression of CD158k/p140/KIR3DL2 in Sezary patients
Blood,
February 1, 2003;
101(3):
1203 - 1203.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nikolova, P. Musette, M. Bagot, L. Boumsell, and A. Bensussan
Engagement of ILT2/CD85j in Sezary syndrome cells inhibits their CD3/TCR signaling
Blood,
July 18, 2002;
100(3):
1019 - 1025.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
